SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venus Remedies sings license agreement with lnfex Therapeutics to develop MET-X

25 Feb 2025 Evaluate

Venus Remedies has entered into an exclusive license agreement with lnfex Therapeutics, a UK-based anti-infectives specialist for the clinical development of MET-X. This agreement authorizes the company to spearhead the clinical development, registration, and commercialization of MET-X, an innovative Metallo-Beta-Lactamase (MBL) inhibitor. The initial development phase will focus on integrating MET-X with meropenem to tackle drug-resistant Gram-negative bacteria, with the company holding exclusive marketing rights within India.

Under the terms of the agreement, the company will commence with a Phase I involving healthy volunteers in India, evaluating MET-X in combination with meropenem. Following successful Phase I outcome, the focus will shift to Phase II/III trials targeting drug-resistant Complicated Urinary Tract Infections (cUTls), prevalent in hospital settings.

This strategic move is aligned with the company’s extensive experience in antibiotic R&D and critical care, enhancing its leadership in Indian critical care landscape. The company’s formidable position in meropenem marketing and manufacturing will facilitate the integration of MET-X in existing and prospective antibiotic strategies.

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.

Venus Remedies Share Price

1066.80 26.85 (2.58%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×